Evidence map›Paper›PMID 39372431›Full record

ArticleFrontiers in bioengineering and biotechnology2024

Automated CRISPR/Cas9-based genome editing of human pluripotent stem cells using the StemCellFactory.

Bastian Nießing, Yannik Breitkreuz, Andreas Elanzew, Marcelo A S de Toledo, Peter Vajs, Marina Nolden, Frederik Erkens, Paul Wanek, Si Wah Christina Au Yeung, Simone Haupt and 5 more

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Bastian Nießing *Fraunhofer Institute for Production Technology (FHG), Aachen, Germany.
Yannik Breitkreuz *LIFE & BRAIN GmbH, Bonn, Germany.
Andreas ElanzewInstitute of Reconstructive Neurobiology, University of Bonn, Bonn, Germany.
Marcelo A S de ToledoInstitute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Peter VajsFraunhofer Institute for Production Technology (FHG), Aachen, Germany.
Marina NoldenFraunhofer Institute for Production Technology (FHG), Aachen, Germany.
Frederik ErkensFraunhofer Institute for Production Technology (FHG), Aachen, Germany.
Paul WanekInstitute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Si Wah Christina Au YeungInstitute of Reconstructive Neurobiology, University of Bonn, Bonn, Germany.
Simone HauptLIFE & BRAIN GmbH, Bonn, Germany.
Niels KönigFraunhofer Institute for Production Technology (FHG), Aachen, Germany.
Michael PeitzLIFE & BRAIN GmbH, Bonn, Germany.
Robert H SchmittFraunhofer Institute for Production Technology (FHG), Aachen, Germany.
Martin ZenkeInstitute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Oliver BrüstleLIFE & BRAIN GmbH, Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR/Cas9 genome editing is a rapidly advancing technology that has the potential to accelerate research and development in a variety of fields. However, manual genome editing processes suffer from limitations in scalability, efficiency, and standardization. The implementation of automated systems for genome editing addresses these challenges, allowing researchers to cover the increasing need and perform large-scale studies for disease modeling, drug development, and personalized medicine. In this study, we developed an automated CRISPR/Cas9-based genome editing process on the StemCellFactory platform. We implemented a 4D-Nucleofector with a 96-well shuttle device into the StemCellFactory, optimized several parameters for single cell culturing and established an automated workflow for CRISPR/Cas9-based genome editing. When validated with a variety of genetic backgrounds and target genes, the automated workflow showed genome editing efficiencies similar to manual methods, with indel rates of up to 98%. Monoclonal colony growth was achieved and monitored using the StemCellFactory-integrated CellCelector, which allowed the exclusion of colonies derived from multiple cells or growing too close to neighbouring colonies. In summary, we demonstrate the successful establishment of an automated CRISPR/Cas9-based genome editing process on the StemCellFactory platform. The development of such a standardized and scalable automated CRISPR/Cas9 system represents an exciting new tool in genome editing, enhancing our ability to address a wide range of scientific questions in disease modeling, drug development and personalized medicine.

Indexed as

automationCRISPR/Cas9genome editinginduced pluripotent stem cellsiPS cellsStemCellFactory

Identifiers

PMID39372431
PMCPMC11449837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.